Operates outpatient mental-health clinics that provide magnetic-stimulation and SPRAVATO treatments to patients, and sells NeuroStar systems and treatment sessions to psychiatrists and other healthcare providers.
10-K for FY2025, filed Mar 17, 2026Neuronetics, Inc. (the “Company” or “Neuronetics” or the “Registrant”) believes that mental health is as important as physical health. As a…View ↗
Currently operating through 93 company-operated Treatment Centers and company-supported healthcare provider practice groups, Greenbrook is…View ↗
We primarily market and sell the NeuroStar Advanced Therapy System and recurring treatment sessions to psychiatrists, with primary care…View ↗
Clinic revenue is the largest stream: third-party payors fund TMS, SPRAVATO and other mental-health treatments performed at Neuronetics clinics. Providers pay for systems when shipped and for treatment-session codes as they are delivered.
10-K for FY2025, filed Mar 17, 2026Clinic Revenues. Clinic revenue, consisting of TMS services, SPRAVATO® sales and other mental wellness services is determined based on net…View ↗
Clinic revenue is recognized at a point in time upon the performance of services under contracts with customers and represents the…View ↗
Payment terms typically require payment upon shipment of the System and additional payments as access codes are delivered, which can span…View ↗
A treatment session is a single use consumable that is delivered via an encrypted activation code and is required in order for a clinician…View ↗
10-K for FY2025, filed Mar 17, 2026
FY2025 revenue by product or service ↗$149.2M
10-K for FY2025, filed Mar 17, 2026
$149.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Products and Other
|
42% |
Products and Other, FY2025
$62.2M Sources
|
|
|
Service
Sold outright
10-K for FY2025, filed Mar 17, 2026 |
58% |
Service, FY2025
$87M Sources
|
Sold outright |
Psychiatrists are the main buyers of NeuroStar systems and treatment sessions through the direct sales team, with some primary care physicians and pain specialists also buying. International sales go through distributors, while patients receive care at Greenbrook clinics, with reimbursement from public programs and commercial insurers.
10-K for FY2025, filed Mar 17, 2026We primarily market and sell the NeuroStar Advanced Therapy System and recurring treatment sessions to psychiatrists, with primary care…View ↗
We have structured our sales and customer support team with specialized roles to sell our NeuroStar Advanced Therapy Systems and recurring…View ↗
InternationalView ↗
Clinic revenue is recognized at a point in time upon the performance of services under contracts with customers and represents the…View ↗
No. It lost $39M in FY2025.
10-Q for Q3 FY2026, filed Nov 4, 2026
−$1.7MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
8-K, filed Aug 11, 2026
Total revenue between $160 million and $164 million, as compared to prior guidance of $160 million and $166 million;View ↗
8-K, filed Aug 17, 2026
(c) As previously disclosed, the Board of Directors of the Company (the “Board”) appointed Nir Naor as the Company’s Executive Vice…View ↗
Growing. Revenue grew 2.7x in 4 years, from $55.3M in FY2021 to $149.2M in FY2025, about 28% a year.
Clinic-based care
The earlier report centered on designing, developing and selling NeuroStar systems and treatment sessions to providers. The latest report also describes company-operated clinics delivering magnetic-stimulation and SPRAVATO care directly to patients.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 17, 2026
Competes with Brainsway, Apollo TMS, Magstim, MagVenture, CloudTMS, and Nexstim
10-K for FY2025, filed Mar 17, 2026We have competitors that sell other forms of TMS therapy, including Brainsway, Apollo TMS, Magstim, MagVenture, CloudTMS and Nexstim, that…View ↗
Loading...